In a groundbreaking move, the Chinese mainland's National Healthcare Security Administration has set pricing guidelines for innovative brain-computer interface (BCI) services. 🚀 This initiative paves the way for integrating futuristic neurotech into mainstream clinical practice.
The guidelines detail fees for both invasive procedures—such as implantation and removal—and non-invasive adaptations. BCI technology enables direct communication between the brain and external devices using implanted electrodes or external sensors. 🤖
Unlike fully invasive solutions like Elon Musk's Neuralink, clinical trials on the Chinese mainland are adopting a semi-invasive approach with a device called Neural Electronic Opportunity (NEO). Developed by scientists from Tsinghua University under Hong Bo’s leadership, the NEO device places a tiny electrode detector between the skull and dura mater, avoiding direct brain tissue damage while capturing high-quality signals.
Early trials, including a pioneering surgery at Capital Medical University Xuanwu Hospital in Beijing, have already shown promising results as a patient regained hand movement with the help of an air-filled glove. With three successful surgeries so far, plans are underway for 30-50 clinical cases in 2025, along with the establishment of a production line at the Zhangjiang Cell Industrial Park in Shanghai capable of producing 10,000 sets annually. 🔥
Looking ahead, the next version of the NEO device is expected to be as compact as a coin, featuring 64 channels and utilizing lighter materials with advanced chip technology to boost performance. This development marks an exciting milestone at the intersection of healthcare and technology.
Reference(s):
China sets pricing guidelines for brain-computer interface services
cgtn.com
